A company playing a role in the search for a Covid-19 vaccine has secured a new 49,000 sq ft home at Oxford Technology Park.
The Native Antigen Company has signed a pre-let for a new purpose-built R&D and manufacturing centre at the park.
This new 49,000 sq ft two-storey building, which will be ready by Summer 2021, will accommodate a mix of bespoke laboratory, office and logistics operations.
Chief operating officer Nick Roesen said: “The site presents a perfect opportunity to expand our operations. The location is right for us and was made very attractive with the ability to design the interior space to suit our business requirements.
“We are also excited about being part of a new science community at the Oxford Technology Park.”
In April, The Native Antigen Company joined forces with biotechnology business Oxgene to help with work on vaccines and, more recently, introduced new antibodies which will aid further research.
Its new home is under construction alongside another 30,000 sq ft building which will offer suites from 4,000 sq ft – also for occupation next Summer.
Oxford Technology Park’s next phase will be flexible hi-tech buildings suitable for lab, R&D and light manufacturing.
A Premier Inn hotel and Beefeater restaurant opened in January 2020.
Angus Bates, director at Hill Street Holdings which owns the park, said: “Oxford is such an amazing place and we have been overwhelmed by the scale of demand for what we are building.
“Our approach is to build flexible spaces with the power, data and construction technology to cater for any form of requirement from science and technology companies.
“We have great plans for the next phases including smaller grow-on units as well as more large buildings.”
Bidwells and Benedicts are letting agents.
© Thames Tap (powered by ukpropertyforums.com).
Sign up to receive your free weekly Thames Tap newsletter here.
